Skip to content

Contact +44 (0) 20 7060 7474 email us

Diabetes

World Diabetes Market Analysis 2009-2023

 

Publication Date February 2009
Publisher Visiongain
Product Type Report
Pages 121
ISBN Number not applicable
Product Code VIS00096

Price

£1,499.00
approximately: $2,270 | €1,673

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. As discussed in this new visiongain report - World Diabetes Market Analysis, 2009-2023 - The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder.

In 2007, the diabetes treatment market worldwide was worth over $25 billion, and had double-digit growth from the year before. Consequently, it is one of the largest sectors in the global healthcare industry. All segments of the diabetes therapy market have been expanding, but which will grow fastest in years to come? What are the key therapeutic and commercial trends to watch? How will the principal national markets perform from 2009 to 2023? What will happen to the current leading products/therapies? How does diabetes overlap with obesity? This report will answer those and other crucial questions about this large, increasingly important pharmaceutical market.

This visiongain report - World Diabetes Market Analysis, 2009-2023 - provides in-depth analysis of the markets for insulins, insulin analogues and oral anti-diabetics. This report also covers the new GLP-1 analogues - such as Byetta and liraglutide - as well as potentially revolutionary insulin delivery technologies. Our study includes detailed sales forecasts for crucial products and market areas, providing the information you need to assess commercial aspects of the diabetes market fully. We cover both sales worldwide and for leading national markets, present and future. In addition to consultation with relevant experts - including interview transcripts - this original research involved a detailed study of policy documents, industrial reports and current developments, including R&D pipelines and line extensions. Importantly, visiongain applied techniques such as financial forecasting and analyses of market drivers and restraints. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else.

Highlights of World Diabetes Market Analysis, 2009-2023 include:

  • Analyses of the strengths, weaknesses, opportunities and threats that will affect the global diabetes market, particularly drivers and restraints
  • Sales forecasts for major drugs and discussion of prominent companies' activities
  • Separate analyses and forecasts for the oral anti-diabetics and insulin analogues markets
  • Regional analyses for the United States, Europe, Japan, China and India, all divided into sales forecasts for oral anti-diabetics and insulin analogues
  • Expert opinion - derived from original research interviews - discussing diabetes research, promising drugs and the commercial and therapeutic significance of the obesity epidemic on diabetes incidence and treatment, present and future
  • Analyses of crucial future trends, including ultra-long-acting drugs and novel insulin-delivery technologies, as well as more-radical developments.

Why you should buy this report:

  • To receive forecasts of global revenue trends for diabetes treatments from 2009 to 2023
  • To gain in-depth sales forecasts, from 2009 to 2023, covering strengths and weaknesses of key products and sub-markets
  • To gain an understanding of all sectors of the diabetes market, including commercial analyses of individual drugs, drug classes, pipelines and regional markets
  • To discover insight from original interviews with key opinion leaders (KOLs)
  • To find out how the diabetes market is set to change dramatically over the next fifteen years
  • To discover how the diabetes management sector is evolving worldwide in terms of diagnosis, assessment, treatment and patient compliance
  • To discover exactly why diabetes is a major concern for governments, and why this serious chronic illness is one of the most important global healthcare issues, with hundreds of millions of people suffering from diabetes and hundreds of million more currently at risk

Visiongain predicts continuing expansion of the market for the whole range of diabetes treatments, driven by increasing disease incidence as well as improvements to diagnoses and treatment access, especially in developing countries. Successful participating companies will benefit as a result, gaining market prominence from high-value products. The healthcare industry cannot afford to ignore current developments in diabetes treatment, as shown in this report. Diabetes is arguably the greatest healthcare threat in developed countries and a rising scourge in countries such as China, India and Brazil. Pharmaceutical, biotechnological and diagnostics companies cannot afford to overlook this developing field, especially for innovative therapies.

Contents

  • 1 Executive Summary
    • 1.1 Crucial Details of The Diabetes Market Trajectory
      • 1.1.1 Visiongain Predicts The Diabetes Market Will Approach $64 Billion by 2023
      • 1.1.2 Diabetes Is Spreading at An Epidemic Rate: The Need for Pharmaceuticals Is Growing
      • 1.1.3 Diabetes Care Works: The Market Will Expand Significantly
      • 1.1.4 Awareness, Advocacy, and Government Spending Aimed at Diabetes Are All Expanding
    • 1.2 Aims, Scope and Format of The Report
    • 1.3 Research Methodology
  • 2 Introduction
    • 2.1 What Is Diabetes Mellitus?
      • 2.1.1 Symptoms of Diabetes
      • 2.1.2 Type 1 Diabetes
      • 2.1.3 Type 2 Diabetes
      • 2.1.4 Gestational Diabetes
      • 2.1.5 Other Types of Diabetes
      • 2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (Igt) and Metabolic Syndrome
    • 2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve Damage
    • 2.3 Obesity: The Major Diabetes Risk Factor
    • 2.4 Other Risk Factors: Age, Genetics, Race
    • 2.5 Diagnosis: Guidelines Are Subject to Change
    • 2.6 Prevalence: by All Measures, Diabetes Rates Are Rising Epidemically
    • 2.7 The Economic Costs of Diabetes: $58 Billion in The US, $41 Billion in Africa
    • 2.8 Treatments
      • 2.8.1 Insulin: A Central Therapeutic Product
        • 2.8.1.1 Crucial Insulin Characteristics: Onset, Peak, and Duration Modifications
        • 2.8.1.2 Invasive Insulin Delivery Methods: Injections, Pumps, Insulin Jets
        • 2.8.1.3 Moving Away from Injections? Alternative Delivery Methods under Development, and Set to Revolutionize The Market
      • 2.8.2 Medications
      • 2.8.3 More Novel Therapies? A New Discovery about How Insulin Works May Lead to New Drugs
    • 2.9 Diabetes Treatment Noncompliance Rates 25% to 90%
  • 3 World Diabetes Market, 2008-2023
    • 3.1 Market Forecast, 2008-2023
    • 3.2 Leading Drugs
      • 3.2.1 Byetta: Potentially Revolutionary Blockbuster
      • 3.2.2 Oral Antidiabetics Forecast
      • 3.2.3 Actos
      • 3.2.4 Avandia: Unlikely to Survive past 2013
      • 3.2.5 Januvia
      • 3.2.6 Avandamet
      • 3.2.7 Human Insulin and Analogues Forecast
      • 3.2.8 Lantus
      • 3.2.9 Novorapid
      • 3.2.10 Humalog
      • 3.2.11 Novomix
      • 3.2.12 Actraphane Hm
      • 3.2.13 Levemir
      • 3.2.14 Other Diabetes-Related Drugs: Symlin up and Kinedak down
    • 3.3 Alternative Delivery Methods: The Possibilities to Watch
  • 4 Leading Companies
    • 4.1 Novo Nordisk
    • 4.2 Takeda
    • 4.3 Sanofi-Aventis
    • 4.4 Eli Lilly
    • 4.5 Amylin
    • 4.6 Pipeline Developments
      • 4.6.1 Liraglutide
      • 4.6.2 Other Glp-1 Analogues
      • 4.6.3 Dpp-4 Inhibitors
      • 4.6.4 Biguanides
      • 4.6.5 New Therapy Class: Sodium-Glucose Cotransporter-2 (Sglt2) Inhibitors
      • 4.6.6 Insulin Pipelines: Some New Insulins, but Mostly Focused on Delivery
        • Methods
      • 4.6.7 Pipeline for A Cure?
  • 5 World Market Analysis by Region
    • 5.1 United States
    • 5.2 Europe
    • 5.3 Japan
    • 5.4 India: Becoming The Largest World Market?
    • 5.5 China: Another Region to Watch Closely
    • 5.6 The Rest of The World
  • 6 SWOT (Strengths, Weaknesses, Opportunities, Threats) Analysis
    • 6.1 Strengths: Diabetes Is Increasing, and Diabetes Drugs Work
    • 6.2 Weaknesses
    • 6.3 Opportunities
    • 6.4 Threats
      • 6.4.1 The Most Significant Threat: Potential Changes in Drug Approval
        • Guidelines
      • 6.4.2 Other Significant Threats
    • 6.5 Interview with Fred Levine, M.D., Ph.D. Professor, Burnham Institute for Medical
      • Research; Director, Sanford Children's Health Research Center
      • 6.5.1 on Alternative Delivery Methods:
      • 6.5.2 on Cardiovascular Problems Associated with Oral Antidiabetics
      • 6.5.3 on Obesity and Diabetes
      • 6.5.4 on Byetta
      • 6.5.5 on Stem Cell Therapy/Cure
    • 6.6 Interview with Björn Tyrberg, Phd. Associate Professor at Burnham Institute for
      • Medical Research, Diabetes and Obesity Research Center.
      • 6.6.1 on Diet and Diabetes
      • 6.6.2 on Byetta and Liraglutide
  • 7 Conclusions: Diabetes is a High Growth Market
    • 7.1 Diabetes Increasing Worldwide: High Prevalence and Incidence
    • 7.2 World Market Value by 2023
    • 7.3 How will Oral Antidiabetic and Insulin Sales Compare in the Future?
  • List of Tables
    • Table 2.1 Diabetes Numbers in Millions, by WHO Region
    • Table 2.2 Secondary Costs of Diabetes in the US
    • Table 2.3 Total Costs of Diabetes to Africa
    • Table 2.4 Diabetes World Market, 2007
    • Table 2.5 Insulin Types, by Onset Rate
    • Table 2.6 Alternative Delivery Methods in the Pipeline, by Type and Development Stage, 2008
    • Table 2.7 Antidiabetic Drugs by Class, 2008
    • Table 3.1 Diabetes Sales Forecast, 2008-2023
    • Table 3.2 Sales Forecasts for Oral Antidiabetics and Insulins, 2008-2023
    • Table 3.3 Byetta Sales Forecast, 2008-2023.
    • Table 3.4 Oral Antidiabetic Sales Forecast, 2008-2023
    • Table 3.5 Actos Sales Forecast, 2008-2023
    • Table 3.6 Avandia Sales Forecast, 2008-2023
    • Table 3.7 Januvia Sales Forecast, 2008-2023
    • Table 3.8 Avandamet Sales Forecast 2008-2023
    • Table 3.9 Insulin Sales Forecast 2008-2023
    • Table 3.10 Lantus Sales Forecast, 2008-2023
    • Table 3.11 Novorapid Sales Forecast, 2008-2023
    • Table 3.12 Humalog Sales Forecast, 2008-2023
    • Table 3.13 Novomix Sales Forecast, 2008-2023
    • Table 3.14 Actraphane HM Sales Forecast, 2008-2023
    • Table 3.15 Levemir Sales Forecast, 2008-2023
    • Table 3.16 Symlin Sales Forecast, 2008-2023
    • Table 3.17 Pipeline of Alternative Methods of Insulin Delivery, by Method and Development Stage, 2008
    • Table 4.1 Pipeline of Alternative Insulin Delivery Methods, 2008
    • Table 5.1 Sales and Market Share Forecasts, 2008-2023
    • Table 6.1 SWOT Table for Diabetes Therapies, 2008-2023
  • List of Figures
    • Figure 2.1 Rise in Diabetes Cases, by WHO Region
    • Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007
    • Figure 2.3 Secondary Costs of Diabetes (minus direct medical costs), 2007
    • Figure 3.1 Total Diabetes Sales Forecast, 2008-2023
    • Figure 3.2 Diabetes Market, by Type and Market Share %, 2007
    • Figure 3.3 Sales Forecast for Oral Antidiabetics and Insulins, 2008-2023
    • Figure 3.4 Byetta Sales Forecast, 2008-2023
    • Figure 3.5 Oral Antidiabetic Sales Forecast, 2008-2023
    • Figure 3.6 Top Oral Antidiabetics, by Market Share, 2008
    • Figure 3.7 Actos Sales Forecast, 2008-2023
    • Figure 3.8 Avandia Sales Forecast 2008-2023
    • Figure 3.9 Januvia Sales Forecast, 2008-2023
    • Figure 3.10 Avandamet Sales Forecast, 2008-2023
    • Figure 3.11 Insulin Sales Forecast 2008-2023
    • Figure 3.12 Top-selling Insulins by Market Share
    • Figure 3.13 Lantus Sales Forecast, 2008-2023
    • Figure 3.14 Novorapid Sales Forecast, 2008-2023
    • Figure 3.15 Humalog Sales Forecast, 2008-2023
    • Figure 3.16 Novomix Sales Forecast, 2008-2023
    • Figure 3.17 Actraphane HM Sales Forecast, 2008-2023
    • Figure 3.18 Levemir Sales Forecast, 2008-2023
    • Figure 3.19 Symlin Sales Forecast, 2008-2023
    • Figure 4.1 Leading Companies by Market Share, 2007
    • Figure 5.1 Regional Sales Forecasts, 2008-2023
    • Figure 5.2 Market Share by Region, 2013
    • Figure 5.3 Market Share by Region, 2018
    • Figure 5.4 United States Sales Forecast, 2008-2023
    • Figure 5.5 European Sales Forecasts, 2008-2023
    • Figure 5.6 Japanese Sales Forecast, 2008-2023
    • Figure 5.7 Indian Sales Forecast, 2008-2023
    • Figure 5.8 Chinese Sales Forecast, 2008-2023
    • Figure 5.9 Rest of the World Sales Forecast, 2008-2023
  • Companies Listed
    • Abbott
    • Altea Therapeutics
    • Amylin
    • AstraZeneca
    • Aventis
    • Battelel Medical Device Solutions
    • Baxter International
    • Bayhill Therapeutics
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Burnham Institute
    • Chong Kun Dang
    • CPEX/Bentley
    • Diabetology
    • Eli Lilly
    • Emisphere
    • Forest
    • Galenix
    • Generex Biotechnology
    • GlaxoSmithKline
    • Hoechst
    • Human Genome Sciences
    • Ipsen
    • Lifescan
    • MannKind
    • Merck
    • Merrion
    • Novartis
    • Novo Nordisk
    • Ono
    • Oramed
    • Otsuka
    • Pfizer
    • Phenomix
    • Phosphagenics
    • Qdose
    • Roche
    • Sanofi-aventis
    • Servier
    • Takeda
    • Ypsomed